SomaLogic’s proprietary SOMAscanTM proteomic assay overcomes many of the limitations of current technologies and provides a “one stop shop” for the entire process from basic biomarker discovery to validated companion diagnostic. The SOMAscan technology also gives unprecedented protein biomarker support for drug discovery and development, including target discovery and validation, mechanism of action, prediction of efficacy, patient stratification, and drug response monitoring.
Steven Williams, M.D., Ph.D., Chief Medical Officer of SomaLogic, will present the company’s technology in a talk at the ELRIG ‘Companion Diagnostics’ Conference entitled:
“Unlocking protein biomarker discovery for diagnostics and therapeutics; Rapid translation to diagnostic products”
“We are delighted that this is the first formal European availability of our technology,” said Dr. Williams. “We look forward to building on our current strong collaborations in the UK and establishing new ones that will create additional opportunities for building transformative health care products.”